Search

Your search keyword '"Green, Damian"' showing total 550 results
Start Over Author "Green, Damian" Search Limiters Full Text
550 results on '"Green, Damian"'

2. Responsible AI Implementation: A Human-centered Framework for Accelerating the Innovation Process

Author

Tjondronegoro, Dian, Yuwono, Elizabeth, Richards, Brent, Green, Damian, and Hatakka, Siiri

Subjects
Computer Science - Artificial Intelligence, Computer Science - Human-Computer Interaction
Abstract

There is still a significant gap between expectations and the successful adoption of AI to innovate and improve businesses. Due to the emergence of deep learning, AI adoption is more complex as it often incorporates big data and the internet of things, affecting data privacy. Existing frameworks have identified the need to focus on human-centered design, combining technical and business/organizational perspectives. However, trust remains a critical issue that needs to be designed from the beginning. The proposed framework expands from the human-centered design approach, emphasizing and maintaining the trust that underpins the process. This paper proposes a theoretical framework for responsible artificial intelligence (AI) implementation. The proposed framework emphasizes a synergistic business technology approach for the agile co-creation process. The aim is to streamline the adoption process of AI to innovate and improve business by involving all stakeholders throughout the project so that the AI technology is designed, developed, and deployed in conjunction with people and not in isolation. The framework presents a fresh viewpoint on responsible AI implementation based on analytical literature review, conceptual framework design, and practitioners' mediating expertise. The framework emphasizes establishing and maintaining trust throughout the human-centered design and agile development of AI. This human-centered approach is aligned with and enabled by the privacy by design principle. The creators of the technology and the end-users are working together to tailor the AI solution specifically for the business requirements and human characteristics. An illustrative case study on adopting AI for assisting planning in a hospital will demonstrate that the proposed framework applies to real-life applications., Comment: 18 pages, 7 Figures

Published
2022

3. Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR T cell therapies in autoimmunity

Author

Bodansky, Aaron, Yu, David J.L., Rallistan, Alysa, Kalaycioglu, Muge, Boonyaratanakornki, Jim, Green, Damian J., Gauthier, Jordan, Turtle, Cameron J., Zorn, Kelsey, O'Donovan, Brian, Mandel-Brehm, Caleigh, Asaki, James, Kortbawi, Hannah, Kung, Andrew F., Rackaityte, Elze, Wang, Chung-Yu, Saxena, Aditi, de Dios, Kimberly, Masi, Gianvito, Nowak, Richard J., O'Connor, Kevin C., Li, Hao, Diaz, Valentina E., Saloner, Rowan, Casaletto, Kaitlin B., Gontrum, Eva Q., Chan, Brandon, Kramer, Joel H., Wilson, Michael R., Utz, Paul J., Hill, Joshua A., Jackson, Shaun W., Anderson, Mark S., and DeRisi, Joseph L.

Subjects
T cells -- Health aspects, Proteomics -- Analysis, Cellular therapy -- Complications and side effects -- Patient outcomes, Viral antibodies -- Health aspects, Antibodies -- Health aspects, Health care industry, Analysis, Complications and side effects, Patient outcomes, Health aspects
Abstract

Given the global surge in autoimmune diseases, it is critical to evaluate emerging therapeutic interventions. Despite numerous new targeted immunomodulatory therapies, comprehensive approaches to apply and evaluate the effects of these treatments longitudinally are lacking. Here, we leveraged advances in programmable-phage immunoprecipitation methodology to explore the modulation, or lack thereof, of autoantibody profiles, proteome-wide, in both health and disease. Using a custom set of over 730,000 human-derived peptides, we demonstrated that each individual, regardless of disease state, possesses a distinct and complex constellation of autoreactive antibodies. For each individual, the set of resulting autoreactivites constituted a unique immunological fingerprint, or "autoreactome," that was remarkably stable over years. Using the autoreactome as a primary output, we evaluated the relative effectiveness of various immunomodulatory therapies in altering autoantibody repertoires. We found that therapies targeting B cell maturation antigen (BCMA) profoundly altered an individual's autoreactome, while anti-CD19 and anti-CD20 therapies had minimal effects. These data both confirm that the autoreactome comprises autoantibodies secreted by plasma cells and strongly suggest that BCMA or other plasma cell- targeting therapies may be highly effective in treating currently refractory autoantibody-mediated diseases., Introduction Autoantibodies have been identified in a wide range of autoimmune diseases (1-4). In many cases these autoantibodies are directly pathogenic (5-10), while in others they amplify or support T [...]

Published
2024
Full Text
View/download PDF

5. Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma

Author

Coffey, David G., Maura, Francesco, Gonzalez-Kozlova, Edgar, Diaz-Mejia, J. Javier, Luo, Ping, Zhang, Yong, Xu, Yuexin, Warren, Edus H., Dawson, Travis, Lee, Brian, Xie, Hui, Smith, Eric, Ciardiello, Amanda, Cho, Hearn J., Rahman, Adeeb, Kim-Schulze, Seunghee, Diamond, Benjamin, Lesokhin, Alexander, Kazandjian, Dickran, Pugh, Trevor J., Green, Damian J., Gnjatic, Sacha, and Landgren, Ola

Published
2023
Full Text
View/download PDF

6. Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma

Author

Hirayama, Alexandre V., Kimble, Erik L., Wright, Jocelyn H., Fiorenza, Salvatore, Gauthier, Jordan, Voutsinas, Jenna M., Wu, Qian, Yeung, Cecilia C. S., Gazeau, Nicolas, Pender, Barbara S., Kirchmeier, Delaney R., Torkelson, Aiko, Chutnik, Abigail N., Cassaday, Ryan D., Chapuis, Aude G., Green, Damian J., Kiem, Hans-Peter, Milano, Filippo, Shadman, Mazyar, Till, Brian G., Riddell, Stanley R., Maloney, David G., and Turtle, Cameron J.

Published
2024
Full Text
View/download PDF

7. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

Author

Gazeau, Nicolas, Liang, Emily C., Wu, Qian “Vicky”, Voutsinas, Jenna M., Barba, Pere, Iacoboni, Gloria, Kwon, Mi, Ortega, Juan Luis Reguera, López-Corral, Lucía, Hernani, Rafael, Ortiz-Maldonado, Valentín, Martínez-Cibrian, Nuria, Martinez, Antonio Perez, Maziarz, Richard T., Williamson, Staci, Nemecek, Eneida R., Shadman, Mazyar, Cowan, Andrew J., Green, Damian J., Kimble, Erik, Hirayama, Alexandre V., Maloney, David G., Turtle, Cameron J., and Gauthier, Jordan

Published
2023
Full Text
View/download PDF

8. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

Author

Shah, Nina, Aiello, Jack, Avigan, David E, Berdeja, Jesus G, Borrello, Ivan M, Chari, Ajai, Cohen, Adam D, Ganapathi, Karthik, Gray, Lissa, Green, Damian, Krishnan, Amrita, Lin, Yi, Manasanch, Elisabet, Munshi, Nikhil C, Nooka, Ajay K, Rapoport, Aaron P, Smith, Eric L, Vij, Ravi, and Dhodapkar, Madhav

Subjects
Hematology, Immunization, Rare Diseases, Vaccine Related, Biotechnology, Cancer, Orphan Drug, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Consensus, Humans, Immunotherapy, Multiple Myeloma, guidelines as topic, immunotherapy, hematological neoplasms, receptors, chimeric antigen, antineoplastic protocols, receptors, chimeric antigen
Abstract

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor CAR T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable responses and manageable toxicity profiles, however, the appropriate use of these immunotherapy agents can present unique challenges for practicing physicians. Therefore, the Society for Immunotherapy of Cancer convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.

Published
2020

10. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Author

Gauthier, Jordan, Bezerra, Evandro D., Hirayama, Alexandre V., Fiorenza, Salvatore, Sheih, Alyssa, Chou, Cassie K., Kimble, Erik L., Pender, Barbara S., Hawkins, Reed M., Vakil, Aesha, Phi, Tinh-Doan, Steinmetz, Rachel N., Jamieson, Abby W., Bar, Merav, Cassaday, Ryan D., Chapuis, Aude G., Cowan, Andrew J., Green, Damian J., Kiem, Hans-Peter, Milano, Filippo, Shadman, Mazyar, Till, Brian G., Riddell, Stanley R., Maloney, David G., and Turtle, Cameron J.

Published
2021
Full Text
View/download PDF

11. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Author

Holstein, Sarah A., Howard, Alan, Avigan, David, Bhutani, Manisha, Cohen, Adam D., Costa, Luciano J., Dhodapkar, Madhav V., Gay, Francesca, Gormley, Nicole, Green, Damian J., Hillengass, Jens, Korde, Neha, Li, Zihai, Mailankody, Sham, Neri, Paola, Parekh, Samir, Pasquini, Marcelo C., Puig, Noemi, Roodman, G. David, Samur, Mehmet Kemal, Shah, Nina, Shah, Urvi A., Shi, Qian, Spencer, Andrew, Suman, Vera J., Usmani, Saad Z., and McCarthy, Philip L.

Published
2020
Full Text
View/download PDF

12. Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic

Author

Banerjee, Rahul, primary, Poh, Christina, additional, Hirayama, Alexandre V., additional, Gauthier, Jordan, additional, Cassaday, Ryan D., additional, Shadman, Mazyar, additional, Cowan, Andrew J., additional, Till, Brian G., additional, Green, Damian J, additional, Kiem, Hans-Peter, additional, Gopal, Ajay K., additional, and Maloney, David G, additional

Published
2024
Full Text
View/download PDF

13. CD8+chimeric antigen receptor T cells manufactured in absence of CD4+cells exhibit hypofunctional phenotype

Author

Lee, Sang Yun, primary, Lee, Dong Hoon, additional, Sun, Wei, additional, Cervantes-Contreras, Francisco, additional, Basom, Ryan S, additional, Wu, Feinan, additional, Liu, Si, additional, Rai, Richa, additional, Mirzaei, Hamid R, additional, O’Steen, Shyril, additional, Green, Damian J, additional, Shadman, Mazyar, additional, and Till, Brian G, additional

Published
2023
Full Text
View/download PDF

16. Timing of Anti-PD-L1 Antibody Initiation Affects Efficacy/Toxicity of CD19 CAR-T Cell Therapy for Large B-Cell Lymphoma

Author

Hirayama, Alexandre V., primary, Kimble, Erik L., additional, Wright, Jocelyn H., additional, Fiorenza, Salvatore, additional, Gauthier, Jordan, additional, Voutsinas, Jenna M., additional, Wu, Qian "Vicky", additional, Yeung, Cecilia C.S., additional, Gazeau, Nicolas, additional, Pender, Barbara S., additional, Kirchmeier, Delaney R., additional, Torkelson, Aiko, additional, Chutnik, Abigail, additional, Cassaday, Ryan D., additional, Chapuis, Aude G., additional, Green, Damian J, additional, Kiem, Hans-Peter, additional, Milano, Filippo, additional, Shadman, Mazyar, additional, Till, Brian G., additional, Riddell, Stanley R., additional, Maloney, David G, additional, and Turtle, Cameron J., additional

Published
2023
Full Text
View/download PDF

17. Acquired CD38 Gene Deletion as a Mechanism of Tumor Antigen Escape in Multiple Myeloma

Author

Portuguese, Andrew J., primary, Fang, Min, additional, Tuazon, Sherilyn A, additional, Pont, Margot, additional, Qu, Xiaoyu, additional, Shasha, Carolyn, additional, Comstock, Melissa L., additional, Lyons, Justina, additional, Cole, Gabriel, additional, Newell, Evan W, additional, Glynn, Emily, additional, Soma, Lorinda A, additional, and Green, Damian J, additional

Published
2023
Full Text
View/download PDF

19. P1097: CD20 CAR-T THERAPY WITH MB-106 FOR BTK INHIBITOR-REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA (WM)/ LYMPHOPLASMACYTIC LYMPHOMA (LPL) – SINGLE INSTITUTION STUDY

Author

Shadman, Mazyar, primary, Yeung, Cecilia, additional, Redman, Mary W, additional, Yun Lee, Sang, additional, Hoon Lee, Dong, additional, Ra, Susan, additional, Qian, David H, additional, Dezube, Bruce, additional, Chapuis, Aude, additional, Green, Damian, additional, Cowan, Andrew, additional, Cassaday, Ryan, additional, Kiem, Hans-Peter, additional, Warren, Houston E, additional, Milano, Filippo, additional, Gauthier, Jordan, additional, Hirayama, Alexandre, additional, Kwok, Mary, additional, Ujjani, Chaitra, additional, Maloney, David, additional, Gopal, Ajay, additional, and Till, Brian, additional

Published
2023
Full Text
View/download PDF

24. Stratigraphic visualisation for archaeological investigation

Author

Green, Damian Alan, Cosmas, J., and Itagaki, T.

Subjects
631.43, stratigraphy, 3d visualisation, archaeology, computer graphics
Abstract

The principal objective of archaeology is to reconstruct in all possible ways the life of a community at a specific physical location throughout a specific time period. Distinctly separate layers of soil provide evidence for a specific time period. Discovered artefacts are most frequently used to date the layer. An artefact taken out of context is virtually worthless; hence the correct registration of the layer in which they were uncovered is of great importance. The most popular way to record temporal relationships between stratigraphic layers is through the use of the 2D Harris Matrix method. Without accurate 3D spatial recording of the layers, it is difficult if not impossible, to form new stratigraphic correspondences or correlations. New techniques for archaeological recording, reconstruction, visualisation and interpretation in 3D space are described in these works and as a result software has been developed. Within the developed software system, legacy stratigraphy data, reconstructed from archaeological notebooks can be integrated with contemporary photogrammetric models and theodolite point data representations to provide as comprehensive a reconstruction as possible. The new methods developed from this research have the capability to illustrate the progression of the excavation over time. This is made possible after the entry of only two or more strata. Sophisticated, yet easy-to-use tools allow the navigation of the entire site in 3D. Through the use of an animation-bar it is possible to replay through time both the excavation period and the occupation period, that is to say the various time periods in antiquity when human beings occupied these locations. The lack of complete and consistent recording of the soil layers was an issue that proved to be an obstacle for complete reconstruction during the development of these methods. A lack of worldwide archaeological consensus on the methods of stratigraphic recording inhibited development of a universal scientific tool. As a result, new recording methods are suggested to allow more scientific stratigraphic reconstruction.

Published
2003

27. Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy

Author

Hill, Joshua A., primary, Kiem, Erika S., additional, Bhatti, Atif, additional, Liu, Winnie, additional, Keane-Candib, Jacob, additional, Fitzpatrick, Kristin S., additional, Boonyaratanakornkit, Jim, additional, Gardner, Rebecca A., additional, Green, Damian J., additional, Maloney, David G., additional, Turtle, Cameron J., additional, Smith, Jodi M., additional, Gimferrer, Idoia, additional, Blosser, Christopher D., additional, and Jackson, Shaun W., additional

Published
2023
Full Text
View/download PDF

28. Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma

Author

Tuazon, Sherilyn A., Cassaday, Ryan D., Gooley, Theodore A., Sandmaier, Brenda M., Holmberg, Leona A., Smith, Stephen D., Maloney, David G., Till, Brian G., Martin, Daniel B., Chow, Victor A., Rajendran, Joseph G., Fisher, Darrell R., Matesan, Manuela C., Lundberg, Sally J., Green, Damian J., Pagel, John M., Press, Oliver W., and Gopal, Ajay K.

Published
2021
Full Text
View/download PDF

29. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

Author

National Institutes of Health (US), National Cancer Institute (US), Gazeau, Nicolas, Liang, Emily C., Wu, Qian “Vicky”, Voutsinas, Jenna M., Barba, Pere, Iacoboni, Gloria, Kwon, Mi, Reguera-Ortega, Juan Luis, López-Corral, Lucía, Hernani, Rafael, Ortiz-Maldonado, Valentín, Martínez-Cibrián, Nuria, Pérez-Martínez, Antonio, Maziarz, Richard T., Williamson, Staci, Nemecek, Eneida R., Shadman, Mazyar, Cowan, Andrew J., Green, Damian J., Kimble, Erik, Hirayama, Alexandre V., Maloney, David G., Turtle, Cameron J., Gauthier, Jordan, National Institutes of Health (US), National Cancer Institute (US), Gazeau, Nicolas, Liang, Emily C., Wu, Qian “Vicky”, Voutsinas, Jenna M., Barba, Pere, Iacoboni, Gloria, Kwon, Mi, Reguera-Ortega, Juan Luis, López-Corral, Lucía, Hernani, Rafael, Ortiz-Maldonado, Valentín, Martínez-Cibrián, Nuria, Pérez-Martínez, Antonio, Maziarz, Richard T., Williamson, Staci, Nemecek, Eneida R., Shadman, Mazyar, Cowan, Andrew J., Green, Damian J., Kimble, Erik, Hirayama, Alexandre V., Maloney, David G., Turtle, Cameron J., and Gauthier, Jordan

Abstract

Chimeric antigen receptor-engineered (CAR)-T cell therapy remains limited by significant toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The optimal management of severe and/or refractory CRS/ICANS remains ill-defined. Anakinra has emerged as a promising agent based on preclinical data, but its safety and efficacy in CAR-T therapy recipients are unknown. The primary objective of this study was to evaluate the safety of anakinra to treat refractory CRS and ICANS after CAR-T therapy. The secondary objective was to evaluate the impact of key treatment-, patient-, and disease-related variables on the time to CRS/ICANS resolution and treatment-related mortality (TRM). We retrospectively analyzed the outcomes of 43 patients with B cell or plasma cell malignancies treated with anakinra for refractory CRS or ICANS at 9 institutions in the United States and Spain between 2019 and 2022. Cause-specific Cox regression was used to account for competing risks. Multivariable cause-specific Cox regression was used to estimate the effect of anakinra dose on outcomes while minimizing treatment allocation bias by including age, CAR-T product, prelymphodepletion (pre-LD) ferritin, and performance status. Indications for anakinra treatment were grade ≥2 ICANS with worsening or lack of symptom improvement despite treatment with high-dose corticosteroids (n = 40) and grade ≥2 CRS with worsening symptoms despite treatment with tocilizumab (n = 3). Anakinra treatment was feasible and safe; discontinuation of therapy because of anakinra-related side effects was reported in only 3 patients (7%). The overall response rate (ORR) to CAR-T therapy was 77%. The cumulative incidence of TRM in the whole cohort was 7% (95% confidence interval [CI], 2% to 17%) at 28 days and 23% (95% CI, 11% to 38%) at 60 days after CAR-T infusion. The cumulative incidence of TRM at day 28 after initiation of anakinra therapy was 0% in the high

Published
2023

30. Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission

Author

Cowan, Andrew J., Stevenson, Philip A., Cassaday, Ryan D., Graf, Solomon A., Fromm, Jonathan R., Wu, David, Holmberg, Leona A., Till, Brian G., Chauncey, Thomas R., Smith, Stephen D., Philip, Mary, Orozco, Johnnie J., Shustov, Andrei R., Green, Damian J., Libby, Edward N., III, Bensinger, William I., Shadman, Mazyar, Maloney, David G., Press, Oliver W., and Gopal, Ajay K.

Published
2016
Full Text
View/download PDF

34. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model

Author

Green, Damian J., Shadman, Mazyar, Jones, Jon C., Frayo, Shani L., Kenoyer, Aimee L., Hylarides, Mark D., Hamlin, Donald K., Wilbur, D. Scott, Balkan, Ethan R., Lin, Yukang, Miller, Brian W., Frost, Sofia.H.L., Gopal, Ajay K., Orozco, Johnnie J., Gooley, Theodore A., Laird, Kelly L., Till, Brian G., Bäck, Tom, Sandmaier, Brenda M., Pagel, John M., and Press, Oliver W.

Published
2015
Full Text
View/download PDF

36. Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)

Author

Hoffman, James E., primary, Lipe, Brea, additional, Melear, Jason, additional, Liedtke, Michaela, additional, Schroeder, Mark A., additional, Niesvizky, Ruben, additional, Strouse, Christopher, additional, Yasenchak, Christopher A., additional, Green, Damian J., additional, Sauer, Jeremy, additional, Wang, Yinghui, additional, Ho, Phoenix, additional, and Abdallah, Al-Ola, additional

Published
2022
Full Text
View/download PDF

37. Plasma Cell Leukemia: A Multicenter Retrospective Study of 130 Patients

Author

Chineke, Iloabueke, primary, Wertheim, Betsy, additional, Roe, Denise, additional, Larsen, Ashley, additional, Vardell, Victoria A., additional, Sborov, Douglas W., additional, Green, Damian J., additional, Liedtke, Michaela, additional, Okoniewski, Marie, additional, Wazir, Mohammed, additional, Nadeem, Omar, additional, Schachter, Levanto, additional, Coffey, David, additional, Gowin, Krisstina L., additional, and DeGraaff, Dominique, additional

Published
2022
Full Text
View/download PDF

38. Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Author

Vinaud Hirayama, Alexandre, primary, Fiorenza, Salvatore, additional, Gauthier, Jordan, additional, Voutsinas, Jenna M., additional, Wu, Qian Vicky, additional, Kimble, Erik L., additional, Pender, Barbara S., additional, Kirchmeier, Delaney R., additional, Di, Henna A., additional, Cassaday, Ryan D., additional, Chapuis, Aude G., additional, Green, Damian J., additional, Kiem, Hans-Peter, additional, Milano, Filippo, additional, Shadman, Mazyar, additional, Till, Brian G., additional, Riddell, Stanley R., additional, Maloney, David G., additional, and Turtle, Cameron J., additional

Published
2022
Full Text
View/download PDF

42. Humoral and cellular responses to SARS-CoV-2 vaccines before and after chimeric antigen receptor–modified T-cell therapy

Author

Gonzalez, Michael A., Bhatti, Atif M., Fitzpatrick, Kristin, Boonyaratanakornkit, Jim, Huang, Meei-Li, Campbell, Victoria L., Hecht, Jessica, Ibrahimi, Sarah, Wanner, Shera N., Green, Damian J., Maloney, David G., Gauthier, Jordan, Cowan, Andrew J., Greninger, Alexander L., Krantz, Elizabeth M., Koelle, David M., and Hill, Joshua A.

Published
2023
Full Text
View/download PDF

44. Humoral and Cellular Responses to SARS-CoV-2 Vaccines Before and After Chimeric Antigen Receptor-Modified T Cell Therapy

Author

Gonzalez, Michael A, primary, Bhatti, Atif M, additional, Fitzpatrick, Kristin, additional, Boonyaratanakornkit, Jim, additional, Huang, Meei-Li, additional, Campbell, Victoria L, additional, Hecht, Jessica, additional, Ibrahimi, Sarah, additional, Wanner, Shera N, additional, Green, Damian J., additional, Maloney, David G., additional, Gauthier, Jordan, additional, Cowan, Andrew J., additional, Greninger, Alexander L, additional, Krantz, Elizabeth M, additional, Koelle, David M, additional, and Hill, Joshua A., additional

Published
2022
Full Text
View/download PDF

45. Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Author

Mawad, Raya, Gooley, Ted A., Rajendran, Joseph G., Fisher, Darrell R., Gopal, Ajay K., Shields, Andrew T., Sandmaier, Brenda M., Sorror, Mohamed L., Deeg, Hans Joachim, Storb, Rainer, Green, Damian J., Maloney, David G., Appelbaum, Frederick R., Press, Oliver W., and Pagel, John M.

Published
2014
Full Text
View/download PDF

47. Safety and Efficacy Comparison of Two Anakinra Dose Regimens for Refractory CRS or Neurotoxicity after CAR T-Cell Therapy

Author

Gazeau, Nicolas, primary, Barba, Pere, additional, Iacoboni, Gloria, additional, Kwon, Mi, additional, Bailen, Rebeca, additional, Reguera, Juan Luis, additional, López-Corral, Lucía, additional, Hernani, Rafael, additional, Ortiz-Maldonado, Valentin, additional, Pérez-Martínez, Antonio, additional, Maziarz, Richard T, additional, Williamson, Staci, additional, Myers, Jessie, additional, Dwinal, Alexandria Hodges, additional, Nemecek, Eneida R., additional, Shadman, Mazyar, additional, Cowan, Andrew J., additional, Green, Damian J., additional, Chow, Victor A., additional, Hirayama, Alexandre V., additional, Maloney, David G., additional, Turtle, Cameron J., additional, and Gauthier, Jordan, additional

Published
2022
Full Text
View/download PDF

48. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

Author

Pagel, John M., Kenoyer, Aimee L., Bäck, Tom, Hamlin, Donald K., Wilbur, D. Scott, Fisher, Darrell R., Park, Steven I., Frayo, Shani, Axtman, Amanda, Orgun, Nural, Orozco, Johnnie, Shenoi, Jaideep, Lin, Yukang, Gopal, Ajay K., Green, Damian J., Appelbaum, Frederick R., and Press, Oliver W.

Published
2011
Full Text
View/download PDF

49. Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma

Author

Chow, Victor A., primary, Cassaday, Ryan D., additional, Gooley, Theodore A., additional, Smith, Stephen D., additional, Sandmaier, Brenda M., additional, Green, Damian J., additional, Orozco, Johnnie J., additional, Tuazon, Sherilyn A., additional, Matesan, Manuela, additional, Fisher, Darrell R., additional, Maloney, David G., additional, Press, Oliver W., additional, and Gopal, Ajay K., additional

Published
2021
Full Text
View/download PDF

50. Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL

Author

Shadman, Mazyar, primary, Yeung, Cecilia, additional, Redman, Mary, additional, Lee, Sang Yun, additional, Lee, Dong Hoon, additional, Ra, Susan, additional, Ujjani, Chaitra S., additional, Dezube, Bruce J., additional, Poh, Christina, additional, Warren, Edus H., additional, Chapuis, Aude G., additional, Green, Damian J., additional, Cowan, Andrew J., additional, Cassaday, Ryan D., additional, Kiem, Hans-Peter, additional, Gauthier, Jordan, additional, Turtle, Cameron J., additional, Lynch, Ryan C., additional, Smith, Stephen D., additional, Gopal, Ajay K, additional, Maloney, David G., additional, and Till, Brian G., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results